Group 1 - The core point of the article is that Meixin Technology (SZ 301577) held its fourth board meeting on October 24, 2025, to discuss the revision of the "Strategic Committee Work Rules" [1] - For the fiscal year 2024, Meixin Technology's revenue composition is 97.57% from the manufacturing of computers, communications, and other electronic devices, while other businesses account for 2.43% [1] - As of the report, Meixin Technology has a market capitalization of 2.8 billion yuan [1] Group 2 - The article highlights that the Chinese innovative drug sector has generated $80 billion in overseas licensing deals this year [1] - There is a discussion on the hot secondary market for biomedicine, contrasting with the cooling fundraising environment in the primary market [1]
美信科技：10月24日召开董事会会议